BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Esketamine

Sedation; Dissociation; Abuse and Misuse; and Surcidal Thoughts and Behaviors

Sedation

  • Patients are at risk for sedation after administration of SPRAVATO.

Dissociation

  • Patients are at risk for dissociative or perceptual changes after administration of SPRAVATO.
  • Because of the risks of sedation and dissociation, patients must be monitored for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.

Abuse and Misuse

  • SPRAVATO has the potential to be abused and misused. Consider the risks and benefits of prescribing SPRAVATO prior to use in patients at higher risk of abuse. Monitor patients for signs and symptoms of abuse and misuse¬†
  • Because of the risks of serious adverse outcomes resulting from sedation, dissociation, and abuse and misuse, SPRAVATO is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SPRAVATO REMS.¬†

Suicidal Thoughts and Behaviors

  • Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. SPRAVATO is not approved in pediatric patients.

Approved Risk Evaluation and Mitigation Strategies (REMS)

SPRAVATO (Esketamine) Solution

Patient Counseling Information

Medication Guides

Patient Medication Guide - SPRAVATO

Package Inserts

Esketamine

Updated March 2019